ROS-responsive drug delivery systems for biomedical applications

In the field of biomedicine, stimuli-responsive drug delivery systems(DDSs) have become increasingly popular due to their site-specific release ability in response to a certain physiological stimulus, which may result in both enhanced treatment outcome and reduced side effects. Reactive oxygen species(ROS) are the unavoidable consequence of cell oxidative metabolism. ROS play a crucial part in regulating biological and physiological processes,whereas excessive intracellular ROS usually lead to the oxidation stress which has implications in several typical diseases such as cancer, inflammation and atherosclerosis. Therefore,ROS-responsive DDSs have elicited widespread popularity for their promising applications in a series of biomedical research because the payload is only released in targeted cells or tissues that overproduce ROS. According to the design of ROS-responsive DDSs, the main release mechanisms of therapeutic agents can be ascribed to ROS-induced carrier solubility change, ROS-induced carrier cleavage or ROS-induced prodrug linker cleavage. This review summarized the latest development and novel design of ROS-responsive DDSs and discussed their design concepts and the applications in the biomedical field.

Metal-Organic Framework Nanocarriers for Drug Delivery in Biomedical Applications

Investigation of metal–organic frameworks(MOFs)for biomedical applications has attracted much attention in recent years.MOFs are regarded as a promising class of nanocarriers for drug delivery owing to well-defined structure,ultrahigh surface area and porosity,tunable pore size,and easy chemical functionalization.In this review,the unique properties of MOFs and their advantages as nanocarriers for drug delivery in biomedical applications were discussed in the first section.Then,state-ofthe-art strategies to functionalize MOFs with therapeutic agents were summarized,including surface adsorption,pore encapsulation,covalent binding,and functional molecules as building blocks.In the third section,the most recent biological applications of MOFs for intracellular delivery of drugs,proteins,and nucleic acids,especially aptamers,were presented.Finally,challenges and prospects were comprehensively discussed to provide context for future development of MOFs as efficient drug delivery systems.

Nanodiamonds with powerful ability for drug delivery and biomedical applications:Recent updates on in vivo study and patents

Nanodiamonds are novel nanosized carbon building blocks possessing varied fascinating mechanical,chemical,optical and biological properties,making them significant active moiety carriers for biomedical application.These are known as the most‘captivating’crystals attributed to their chemical inertness and unique properties posing them useful for variety of applications in biomedical era.Alongside,it becomes increasingly important to find,ascertain and circumvent the negative aspects associated with nanodiamonds.Surface modification or functionalization with biological molecules plays a significant role in managing the toxic behavior since nanodiamonds have tailorable surface chemistry.To take advantage of nanodiamond potential in drug delivery,focus has to be laid on its purity,surface chemistry and other considerations which may directly or indirectly affect drug adsorption on nanodiamond and drug release in biological environment.This review emphasizes on the basic properties,synthesis techniques,surface modification techniques,toxicity issues and biomedical applications of nanodiamonds.For the development of nanodiamonds as an effective dosage form,researchers are still engaged in the in-depth study of nanodiamonds and their effect on life interfaces.

Application of Liquid Chromatography-Tandem Mass Spectrometry in Determination of Veterinary Drug Residues

With the long -term and irrational use of veterinary drugs and drug additives in the process of animal feeding, the veterinary drug resi- dues in animals and their additives can be ingested into the human body and pose potential threat to human health. Detection of veterinary drug resi- dues are extremely important practical significance to protect the ecological environment and human health. In recent years, liquid chromatography -tandem mass spectrometry has been widely used in vetednary drug residue detection because of its applicability, qualitative and quantitative fea- tures as well as high sensitivity. This article summarized the application of liquid chromatography -tandem mass spectrometry in detection veterinary drug residues from feed, animal products, arid udne as well as illicit drugs and harmful additives.

Progress in the development and application of plant-based antiviral agents

Plant virus disease is one of the major causes of biological disasters in agriculture worldwide. Given the complexity of transmission media and plant disease infection mechanisms, the prevention and control of plant viral diseases is a great challenge, and an efficient green pesticide is urgently needed. For this reason, when developing candidate drug leads to regulate plant viruses, pesticide experts have focused on characteristics such as low pesticide resistance, eco-friendliness, and novel mechanism. Researchers have also theoretically investigated the molecular targets of viruses infecting agricultural crops. Antiviral screening models have been constructed based on these molecular targets, and the mechanisms of commercial drugs and high-activity compounds have been extensively investigated. After screening, some compounds have been applied in the field and found to have good commercial prospects; these drugs may be used to create new green antiviral pesticides to control plant viruses. This paper reviews the screening, mode of action, development and application of recently used plant-based antiviral agents.

Thinking outside the liver: Induced pluripotent stem cells for hepatic applications

The discovery of induced pluripotent stem cells (iPSCs) unraveled a mystery in stem cell research, after identification of four re-programming factors for generating pluripotent stem cells without the need of embryos. This breakthrough in generating iPSCs from somatic cells has overcome the ethical issues and immune rejection involved in the use of human embryonic stem cells. Hence, iPSCs form a great potential source for developing disease models, drug toxicity screening and cell-based therapies. These cells have the potential to differentiate into desired cell types, including hepatocytes, under in vitro as well as under in vivo conditions given the proper microenvironment. iPSC-derived hepatocytes could be useful as an unlimited source, which can be utilized in disease modeling, drug toxicity testing and producing autologous cell therapies that would avoid immune rejection and enable correction of gene defects prior to cell transplantation. In this review, we discuss the induction methods, role of reprogramming factors, and characterization of iPSCs, along with hepatocyte differentiation from iPSCs and potential applications. Further, we discuss the location and detection of liver stem cells and their role in liver regeneration. Although tumor formation and genetic mutations are a cause of concern, iPSCs still form a promising source for clinical applications.

Recent advances in network pharmacology applications in Chinese herbal medicine

Network pharmacology is a new discipline based on the theory of systems biology and network analysis of biological systems to design the drugs.It comprehensively observes the intervention and influence of drugs on the disease network,and reveals the mystery of multi-molecular drugs synergistically acting on disease.These concepts reflect the ideas of multi-component,multi-target and system regulation,and have many similarities with the research ideas of traditional Chinese medicine,which focuses on syndrome differentiation and treatment,emphasizes the overall understanding of the etiology and pathogenesis.Network pharmacology can be used to predict and identify the target and active component of traditional herbal medicine,to clarify the mechanism of action,to scientifically explain the rules of the prescription,to explore the rules of real-world prescription,to discover new indications and new active compounds,and to study drug relocation,etc.The applications of network pharmacology in traditional herbal medicine were systematically summarized to demonstrate the significant value in these areas.

Advances in studies of phospholipids as carriers in skin topical application

Objective： This article provides an overview of characteristics of phospholipids, the characteristics and influential factors of liposome and microemulsion as carriers for skin delivery of drugs, and the latest advances of the phospholipids carriers in transdermal delivery systems. The perspective is that phospholipids carriers may be capable of a wide range of applications in the transdermal delivery system.

Helicobacter pylori neutrophil-activating protein:From molecular pathogenesis to clinical applications

Helicobacter pylori (H. pylori) neutrophil-activating protein (HP-NAP) was originally identified as a virulence factor of H. pylori for its ability to activate neutrophils to generate respiratory burst by releasing reactive oxygen species. Later on, HP-NAP was also found to be involved in the protection of H. pylori from DNA damage, supporting the survival of H. pylori under oxidative stress. This protein is highly conserved and expressed by virtually all clinical isolates of H. pylori. The majority of patients infected with H. pylori produced antibodies specific for HP-NAP, suggesting its important role in immunity. In addition to acting as a pathogenic factor by activating the innate immunity through a wide range of human leukocytes, including neutrophils, monocytes, and mast cells, HP-NAP also mediates adaptive immunity through the induction of T helper cell type I responses. The pro-inflammatory and immunomodulatory properties of HP-NAP not only make it play an important role in disease pathogenesis but also make it a potential candidate for clinical use. Even though there is no convincing evidence to link HP-NAP to a disease outcome, recent findings supporting the pathogenic role of HP-NAP will be reviewed. In addition, the potential clinical applications of HP-NAP in vaccine development, clinical diagnosis, and drug development will be discussed.

Progress in oncolytic viruses modified with nanomaterials for intravenous application

In oncolytic virus(OV)therapy,a critical component of tumor immunotherapy,viruses selectively infect,replicate within,and eventually destroy tumor cells.Simultaneously,this therapy activates immune responses and mobilizes immune cells,thereby eliminating residual or distant cancer cells.However,because of OVs’high immunogenicity and immune clearance during circulation,their clinical applications are currently limited to intratumoral injections,and their use is severely restricted.In recent years,numerous studies have used nanomaterials to modify OVs to decrease virulence and increase safety for intravenous injection.The most commonly used nanomaterials for modifying OVs are liposomes,polymers,and albumin,because of their biosafety,practicability,and effectiveness.The aim of this review is to summarize progress in the use of these nanomaterials in preclinical experiments to modify OVs and to discuss the challenges encountered from basic research to clinical application.

Research Progress and Suggestions on China’s Drug Registration Management Based on CiteSpace Knowledge Maps

Objective To analyze the research status and hot spots in the field of drug registration in China,and to provide some suggestions for the follow-up research.Methods CiteSpace was used to conduct literature quantitative analysis on 684 related articles from 2012 to 2022,and the knowledge map was drawn.Based on this,the main characteristics and development trends of the related studies were summarized.Results and Conclusion The number of articles published was closely related to the regulatory policy of drug registration reform.The authors of these articles did not have good continuity.Besides,research hot spots were closely related to the actual work,which was mainly around the improvement of the review and approval policy,encouraging innovative drug research and development,improving the level of new drug development and other directions.The follow-up studies should further strengthen the continuity of research and inter-agency collaboration.In addition,biomedical registration may become a new research focus in the future.

工程化外泌体靶向递送药物的抗肿瘤效应

背景:当前治疗肿瘤的药物主要以化学药为主,但存在着耐药和不良反应等问题。外泌体药物递送系统不仅避免了人工合成纳米颗粒药物的毒性,而且增加了药物的生物利用度和生物相容性。通过生物、物理和化学方法对外泌体进行修饰进而打造成一种新型的纳米载药平台。目的:对外泌体药物递送系统的构建策略和在肿瘤疾病中的应用现状以及当前所面临的各种挑战进行了综述。方法:以“Exosomal,tumor,microvesicle,extracellular vesicles,engineered,therapeutics,characterization,isolation,drug delivery,targeting,modification strategies,physics,chemistry,biology”为英文检索词和“外泌体,药物递送,肿瘤”为中文检索词检索PubMed及中国知网数据库,最终纳入了132篇文献进行深入地归纳和探讨。结果与结论:①外泌体提取的技术手段,包括超速离心法、过滤法和试剂盒提取等,这些方法虽然能够高效地分离出外泌体,但是过程繁琐并且耗时较长,无法实现外泌体的大规模提取。②工程化外泌体主要分为4类:基因编辑工程化,通过基因改造提升功能;内源性工程化,利用炎症因子等预处理增强药物递送;外源性工程化,直接在外泌体中封装药物;混合型工程化,结合外泌体与脂质纳米颗粒形成新颗粒。目前部分工程化外泌体已进入癌症治疗的临床试验阶段,但多处于早期阶段。相比较而言,基因工程化外泌体因高靶向性和定制化潜力,被视为未来药物递送的重要方向。③实现工程化外泌体的临床转化还有诸多限制,在技术方面,大规模生产、纯化及载药效率等技术难题亟待解决;在生产方面,高昂成本及批次稳定性问题影响普及;在安全性方面,免疫原性及潜在毒性需全面评估;此外,监管政策的不完善及审批流程的复杂性也构成其临床转化的障碍。④未来需通过技术创新、成本控制、安全性提升及政策完善等多方面努力,推动工程化外泌体的临床转化进程。

Current State of Nanoemulsions in Drug Delivery

Nanoemulsions have attracted great attention in research, dosage form design and pharmacotherapy. This is as a result of a number of attributes peculiar to nanoemulsions such as optical clarity, ease of preparation, thermodynamic stability and increased surface area. Nanoemulsions also known as submicron emulsions serve as vehicles for the delivery of active pharmaceutical ingredients as well as other bioactives. They are designed to address some of the problems associated with conventional drug delivery systems such as low bioavailability and noncompliance. The importance of design and development of emulsion nanocarrier systems aimed at controlling and/or improving required bioavailability levels of therapeutic agents cannot be overemphasized. Reducing droplet sizes to the nanoscale leads to some very interesting physical properties, such as optical transparency and unusual elastic behaviour. This review sheds light on the current state of nanoemulsions in the delivery of drugs and other bioactives. The morphology, formulation, characteristics and characterization of nanoemulsions were also addressed.

Nanotechnological Contribution to Drug Delivery System: A Reappraisal

With the emergence of Nanotechnology, there has been remarkable improvement in the field of drug delivery system over the past decade. Nanotechnology in drug delivery system is an upcoming field and significant research has been conducted in this regard. It has been able to overcome some limitations encountered with the traditional routine drug delivery systems and hence emerged as an effective alternative. This article reviews nanotechnology based different types of drug delivery systems and their therapeutic applications.

Active substance applicator to remove the disturbances in the fluid flow

The paper presents the construction of an automatic applicator of active substance that removes causes of the disturbances in the fluid flow in a system that is under the control. In a particular case, it can be applied to the removal of disturbances in the blood flow in vessels caused by a thrombus formation (e.g. post-operative or due to dialysis treatment). The presented applicator automatically releases the active substance into the system while detecting in real time the abnormal fluid flow. It allows mixing the active substance (e.g. anticoagulant drug) with the controlled medium outside the substance container (e.g. serum) while offering the possibility of the repeated usage.

Smart stimuli-responsive drug delivery systems in spotlight of COVID-19

The world has been dealing with a novel severe acute respiratory syndrome(SARS-CoV-2)since the end of 2019,which threatens the lives of many peopleworldwide.COVID-19 causes respiratory infection with different symptoms,from sneezing and coughing to pneumonia and sometimes gastric symptoms.Researchers worldwide are actively developing novel drug delivery systems(DDSs),such as stimuli-responsive DDSs.The ability of these carriers to respond to external/internal and even multiple stimuli is essential in creating“smart”DDS that can effectively control dosage,sustained release,individual variations,and targeted delivery.To conduct a comprehensive literature survey for this article,the terms“Stimuli-responsive”,“COVID-19”and“Drug delivery”were searched on databases/search engines like“Google Scholar”,“NCBI”,“PubMed”,and“Science Direct”.Many different types of DDSs have been proposed,including those responsive to various exogenous(light,heat,ultrasound andmagnetic field)or endogenous(microenvironmental changes in pH,ROS and enzymes)stimuli.Despite significant progress in DDS research,several challenging issues must be addressed to fill the gaps in the literature.Therefore,this study reviews the drug release mechanisms and applications of endogenous/exogenous stimuli-responsive DDSs while also exploring their potential with respect to COVID-19.

基于多学科协作管理模式结合PDCA质量管理工具对中药注射剂的管控效果分析

目的:探讨多学科协作管理模式结合PDCA质量管理工具用于医院中药注射剂管理的成效,为促进中药注射剂的合理应用提供参考。方法:成立多学科协作管理小组,运用PDCA质量管理工具,采取综合干预措施管控河北省中医院(以下简称“该院”)中药注射剂的临床应用。以2020年为干预前、2021年为第1阶段干预后、2022年为第2阶段干预后,对比干预效果。结果:干预前,该院中药注射剂合理使用率为92.38%(3 008/3 256),第1阶段干预后、第2阶段干预后分别升高至94.64%(3 740/3 952)、97.34%(3 766/3 869),与干预前的差异有统计学意义(P<0.001),中药注射剂不合理使用情况得到明显改善。第2阶段干预后,在超疗程、未冲管方面较第1阶段干预后明显改善,差异均有统计学意义(P<0.001),且未发现中西药混合输注、溶剂剂量不适宜、给药途径不适宜、溶剂种类选择不当等问题。干预后,中药注射剂相关不良反应占药品总不良反应的比例呈逐年降低趋势,尤其是第2阶段干预后较干预前明显降低,差异有统计学意义(P=0.013)。结论:在医院中药注射剂管理中运用多学科协作管理模式结合PDCA质量管理工具,可使管理质量显著提高,该方法值得在医院药事管理中推广。

国家医保谈判药品在我院遴选评价的转化应用探索

目的:积极推进国家医保谈判药品的常态化落地,提升国家医保谈判药品的供应保障水平及透明化程度,促进药品回归临床价值。方法:依据2022年5月河北省卫生健康委员会组织制定下发的《河北省三级公立医疗机构用药(化学药品)目录遴选评价表(试行)》中的评价体系,针对拟遴选入院的61个国家医保谈判药品,从有效性、药学特性、安全性、经济性、其他属性5个维度进行综合评价。结果:47个国家医保谈判西药中,29个药品前3项评分≥50分;34个药品前4项评分≥60分;39个药品总分≥60分;24个药品前3项评分≥50分、前4项评分≥60分、总分≥70分;7个药品前3项评分<50分、前4项评分<60分、总分<70分。14个国家医保谈判中药中,同时满足前3项评分≥50分、前4项评分≥60分、总分≥70分的药品数量与同时满足前3项评分<50分、前4项评分<60分、总分<70分的药品数量均为6个。结论:本研究运用量化评价体系对国家医保谈判药品的有效性、药学特性、安全性、经济性等指标进行全方位评价,赋予量化分值,构建满足医疗机构需求的国家医保谈判药品综合评价数据库,通过综合分数来提取出“优”的国家医保谈判药品,过程快速、科学、公正、透明。

分析多角度光散射在药物质量控制中的应用价值

多角度光散射技术在药物质量控制中有着广泛的应用,该检测技术能够直接针对大分子药物相对分子质量与分布情况进行测定,具有测定范围广以及准确度高等特点,能够为药物质量控制以及标准建立、修订等提供技术参考和指导。本文就多角度光散射技术的特点、原理及在药物质量控制中应用情况进行分析。

某三级甲等医院人工智能辅助医药领域专利申请及授权现状分析

目的促进医院人工智能(AI)辅助医药领域相关专利的发展。方法利用解决方案式全球专利智能检索分析平台(HimmPat)提供的专利检索及分析功能,检索某三级甲等医院(截至2023年10月31日)涉及AI辅助医药领域的相关专利数据,分析该领域专利的申请和授权情况、申请法律状态、授权专利类型、具体技术领域、合作申请情况等。结果该院共申请专利130件,其中38件(29.23%)获得授权;16件(12.31%)为合作申请专利,授权率为50.00%。2017年开始出现相关专利申请,之后申请量呈先逐年增加后下降又回升趋势,授权量自2021年起迅速增长;在审专利申请有56件(43.08%),失效专利申请较多(36件,27.69%);获授权专利中发明专利占比较大(34件,授权率为26.98%),实用新型专利授权仅4件。具体技术集中在智能诊疗和智能健康管理领域。结论该院AI辅助医药领域相关专利申请量保持增长态势,但还存在专利管理人才缺乏、涉及技术领域单一、合作申请少等问题。建议医院巩固智能诊疗和智能健康管理方面的专利申请,加强专利管理人才队伍建设,建立高价值专利培育体系,规范医疗数据标准,培养复合型人才,深化与企业合作,并推动专利转化及在高附加值的AI辅助药品研发方面的研究。